Overview2018-05-02T03:02:32+00:00

Overview

Laidlaw Capital Marketsis a fast growing investment bank, providing capital markets advisory and transaction execution services to healthcare companies. With a client-centric approach, we commit to delivering the firm’s resources before, during and after a successful capital markets transaction
Laidlaw Capital Marketshelps clients gain access to capital through the public markets. Our expertise includes specialized offerings such as:
Initial public offerings (IPOs)
Given Laidlaw Capital Markets success raising capital for companies,wehave expanded ourEquity Capital Markets reach to the IPO market. Our expertiseat identify emerging healthcare companies uniquely separates us from other advisors. Our team of banking, capital markets, institutional sales and research professionals are committed to acting and executing as a unified team in order to deliver compelling results for issuers.

Sandesh Seth
Sandesh Seth

Mr. Seth is Head Of Healthcare Investment Banking at Laidlaw & Company (UK) Ltd. Mr. Seth has over 20 years of experience in healthcare between his work in investment banking (Cowen & Co.), equity research (Bear Stearns, Commonwealth Associates) and in the pharmaceutical industry (Pfizer, Warner, Lambert, Smith Kline in strategic planning, business development and R&D project management). Mr. Seth’s extensive healthcare capital markets experience includes over 150 completed transactions resulting in more than $5 billion in capital raised. Transactions included venture investments, private placements, IPOs, FOs, PIPEs, Convertible and High-Yield Debt. Mr. Seth was also involved with various strategic initiatives such as mergers and acquisitions, leveraged and management buyouts, and licensing and joint ventures. Mr. Seth has an MBA in Finance from New York University; an M.S. in the Pharmaceutical Sciences from the University of Oklahoma Health Center and a B.Sc. in Chemistry from Bombay University. He has published several scientific articles and was awarded the University Regents Award for Research Excellence at the University of Oklahoma. Mr. Seth was designated as Regulatory Affairs Certified (R.A.C.) by the Regulatory Affairs Professionals Society which signifies proficiency with U.S. FDA regulations. He also holds the following Securities Industry Licenses: Series7, 79 and 63.
Matt Dormer
Matt Dormer

Matt Dormer joins Laidlaw & Co. (UK) Ltd. from Summer Street Research Partners. During his time at Summer Street he completed more than 40 transactions which raised over $1.5 billion for biotechnology, medical device, and healthcare IT companies. Matt formerly worked for Wellington Management Company in the portfolio advisor group and previously worked in the equity research group covering the biotechnology sector at Fulcrum Global Partners in New York City. Prior to his experience in equity research, Matt was a scientist for a start-up biotechnology company and a research associate and teaching fellow at Harvard University, where he conducted research on tumor suppressor genes. Matt graduated from Davidson College with a BS in biology and received an MBA in finance from Northeastern University